Results 111 to 120 of about 195,338 (284)
Erythema multiforme during GM-CSF therapy.
A 52-year-old Caucasian man treated with granulocyte-macrophage colonystimulating factor (GM-CSF) developed a cutaneous eruption on legs and ankles with clinical and histologic features of erythema multiforme. Laboratory studies indicated that the eruption occurred at the time of peripheral blood lymphocyte recovery and that it was coincidental with ...
STASI, R +5 more
openaire +3 more sources
LMO7 Suppresses Tumor‐Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1
LMO7 in tumor‐associated macrophages suppresses phagocytosis of tumor cells and limits cytotoxic T lymphocytes infiltration, fostering tumor progression. Mechanistically, LMO7 mediates the ubiquitination and degradation of the phagocytic receptor LRP1, impairing its ability to engulf tumor cells and driving macrophages toward an antitumor phenotype ...
Mengkai Li +12 more
wiley +1 more source
ObjectivesGranulocyte monocyte colony-stimulating factor (GM-CSF) is currently considered a crucial inflammatory mediator and a novel therapeutic target in rheumatoid arthritis (RA), despite the fact that its precise cellular sources remain uncertain. We
Anastasia Makris +5 more
doaj +1 more source
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He +17 more
wiley +1 more source
Regulation of Lymphatic GM-CSF Expression by the E3 Ubiquitin Ligase Cbl-b
Genome-wide association studies as well as lymphatic expression analyses have linked both Cbl-b and GM-CSF to human multiple sclerosis as well as other autoimmune diseases. Both Cbl-b and GM-CSF have been shown to play a prominent role in the development
Sebastian Peer +8 more
doaj +1 more source
Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome
Pharmacological SUMOylation inhibition (SUMOi) counteracts tumor immune evasion by unmasking an immunogenic HLA‐I peptide and neoepitope repertoire. By restoring HLA‐I ligand availability through increased antigen processing and presentation, enhanced proteasomal cleavage, and modulated TAP1 peptide affinity, SUMOi boosts tumor immunogenicity ...
Uta M. Demel +19 more
wiley +1 more source
Barrier protection via Toll-like receptor 2 signaling in porcine intestinal epithelial cells damaged by deoxynivalnol [PDF]
Additional file 2. IPEC-J2 cells pretreated with TLR2 ligand maintained the expression of MCP-1, GM-CSF and TLR2 against DON exposure. IPEC-J2 cells pretreated with or without TLR2 ligand for 24 h were exposed to DON.
Byung-Chul Park +11 more
core +8 more sources
This study identifies the transcription factor ETV1 as a key driver of CD4⁺ T cell‐mediated intestinal inflammation in inflammatory bowel disease (IBD). ETV1 promotes CD4⁺ T cell activation, proliferation, and Th17 differentiation by activating the amino acid transporter SLC7A5, fueling metabolic reprogramming.
Yan Shi +8 more
wiley +1 more source
Driving chronicity in rheumatoid arthritis: perpetuating role of myeloid cells [PDF]
Acute inflammation is a complex and tightly regulated homeostatic process that includes leukocyte migration from the vasculature into tissues to eliminate the pathogen/injury, followed by a pro-resolving response promoting tissue repair.
Achuthan +115 more
core +1 more source
Notch2 Directs aTreg Cell Fate toward Immunoregulation or Inflammatory Pyroptosis
Schematic illustration showing that the Notch2 intracellular domain (NICD2) facilitates pyroptosis resistance in activated Tregs through the RREB1/Foxo1 signaling pathway. In addition, Notch2‐mediated pyroptosis resistance in activated Tregs promotes immunoregulatory capacity, thereby attenuating Th2‐driven inflammatory responses in allergic rhinitis ...
Yue‐Long Qiao +10 more
wiley +1 more source

